Log In
Print
BCIQ
Print
Print this Print this
 

Immuno-PDT, verteporfin (Visudyne) (BPD-MA)

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionLight-activated benzoporphyrin derivative used in photodynamic therapy (PDT)
Molecular Target Not available
Mechanism of ActionPhotodynamic therapy
Therapeutic ModalityMedical Devices: Photodynamic therapy
Latest Stage of DevelopmentMarketed
Standard IndicationChoroidal neovascularization (CNV)
Indication DetailsTreat choroidal neovascularization (CNV); Treat chronic or recurrent central serous chorioretinopathy (CSC); Treat occult choroidal neovascularization (CNV) due to age-related macular degeneration (AMD); Treat occult subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD); Treat patients with evidence of recent or ongoing progression in occult subfoveal choridal neovascularization (CNV); Treat polypoidal choroidal vasculopathy (PCV); Treat predominantly classic subfoveal chorodial neovascularization (CNV); Treat subfoveal choroidal neovascularization (CNV) secondary to wet age-related macular degeneration (AMD)
Regulatory Designation

U.S. - Orphan Drug (Treat chronic or recurrent central serous chorioretinopathy (CSC))

Partner

Novartis AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today